Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 40 Records) |
Query Trace: Neutropenia and EGFR[original query] |
---|
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted oncology 2015 Jun . Guetz Gaetan Des, Landre Thierry, Uzzan Bernard, Chouahnia Kader, Nicolas Patrick, Morere Jean-Franço |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology 2015 Feb 16 (2): 141-51. Yang James Chih-Hsin, Wu Yi-Long, Schuler Martin, Sebastian Martin, Popat Sanjay, Yamamoto Nobuyuki, Zhou Caicun, Hu Cheng-Ping, O'Byrne Kenneth, Feng Jifeng, Lu Shun, Huang Yunchao, Geater Sarayut L, Lee Kye Young, Tsai Chun-Ming, Gorbunova Vera, Hirsh Vera, Bennouna Jaafar, Orlov Sergey, Mok Tony, Boyer Michael, Su Wu-Chou, Lee Ki Hyeong, Kato Terufumi, Massey Dan, Shahidi Mehdi, Zazulina Victoria, Sequist Lecia |
A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung cancer (Amsterdam, Netherlands) 2016 Sep 99 131-6. Usui Kazuhiro, Sugawara Shunichi, Nishitsuji Masaru, Fujita Yuka, Inoue Akira, Mouri Atsuto, Watanabe Hiroshi, Sakai Hiroshi, Kinoshita Ichiro, Ohhara Yoshihito, Maemondo Makoto, Kagamu Hiroshi, Hagiwara Koichi, Kobayashi Kunihiko, |
Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. Cancer biology & therapy 2016 Jun 0. Zwitter Matjaz, Rajer Mirjana, Stanic Karmen, Vrankar Martina, Doma Andrej, Cuderman Anka, Grmek Marko, Kern Izidor, Kovac Vilj |
Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Oncotarget 2016 May . Zhang Minghui, Guo Hongsheng, Zhao Shu, Wang Yan, Yang Maopeng, Yu Jiawei, Yan Yubo, Wang Y |
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. British journal of cancer 2016 Feb 114 (4): 372-80. Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero |
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Annals of oncology : official journal of the European Society for Medical Oncology 2017 9 28 (10): 2443-2450. Shi Y K, Wang L, Han B H, Li W, Yu P, Liu Y P, Ding C M, Song X, Ma Z Y, Ren X L, Feng J F, Zhang H L, Chen G Y, Han X H, Wu N, Yao C, Song Y, Zhang S C, Song W, Liu X Q, Zhao S J, Lin Y C, Ye X Q, Li K, Shu Y Q, Ding L M, Tan F L, Sun |
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations. Investigational new drugs 2017 11 36 (4): 608-614. Tamiya Motohiro, Tamiya Akihiro, Shiroyama Takayuki, Takeoka Sawa, Naito Yujiro, Omachi Naoki, Kimura Yohei, Morishita Naoko, Suzuki Hidekazu, Okamoto Norio, Okishio Kyoichi, Kawaguchi Tomoya, Atagi Shinji, Hirashima Tomono |
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer chemotherapy and pharmacology 2018 May . Imai Hisao, Minemura Hiroyuki, Sugiyama Tomohide, Yamada Yutaka, Kaira Kyoichi, Kanazawa Kenya, Kasai Takashi, Kaburagi Takayuki, Minato Koichi, |
Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2018 12 31 (5): 380-383. ?oupková Helena, Vyzula Rostisl |
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC cancer 2018 Dec 18 (1): 1231. Tsutani Yasuhiro, Miyata Yoshihiro, Masuda Takeshi, Fujitaka Kazunori, Doi Mihoko, Awaya Yoshikazu, Kuyama Shoichi, Kitaguchi Soichi, Ueda Kazuhiro, Hattori Noboru, Okada Morihi |
Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching. Anti-cancer drugs 2019 Mar 30 (3): 295-301. Su ShengFa, Liu LingFeng, Geng YiChao, OuYang WeiWei, Ma Zhu, Li QingSong, Zhao ChaoFen, Li Mei, Wang Yu, Luo DaXian, Yang WenGang, He ZhiXu, Lu Bi |
Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study. Clinical lung cancer 2018 11 19 (6): 484-492. Xie Hounai, Wang Hui, Xu Lin, Li Meng, Peng Yue, Cai Xianyun, Feng Zhen, Ren Wangang, Peng Zhongm |
Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program. Oncology 2018 10 96 (1): 51-58. Hong Sook-Hee, An Ho Jung, Kim Kihyun, Lee Seung Sei, Lee Yun-Gyoo, Yuh Young-Jin, Park I Cheon, Chae Yee Soo, Jang Tae-Won, Kang Jin-Hyou |
Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study. Oncotarget 2019 2 10 (10): 1070-1084. Ogata Takatsugu, Satake Hironaga, Ogata Misato, Hatachi Yukimasa, Maruoka Hayato, Yamashita Daisuke, Hashida Hiroki, Hamada Madoka, Yasui Hisate |
The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis. Mathematical biosciences and engineering : MBE 2019 11 16 (6): 7921-7933. Wu Fa Zong, Song Jing Jing, Zhao Zhong Wei, Huang Xu Fang, Mao Jian Ting, Tu Jian Fei, Chen Min Jiang, Chen Wei Qian, Fang Shi Ji, Zheng Li Yun, Fan Xiao |
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ?75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational lung cancer research 2020 7 9 (3): 459-470. Kozuki Toshiyuki, Nogami Naoyuki, Hataji Osamu, Tsunezuka Yoshio, Seki Nobuhiko, Harada Toshiyuki, Fujimoto Nobukazu, Bessho Akihiro, Takamura Kei, Takahashi Kazuhisa, Satouchi Miyako, Kato Terufumi, Shukuya Takehito, Yamashita Natsumi, Okamoto Hiroaki, Shinkai Tetsu, |
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. Journal of clinical medicine 2020 Jun 9 (6): . Nakao Akira, Hiranuma Osamu, Uchino Junji, Sakaguchi Chikara, Araya Tomoyuki, Hiraoka Noriya, Ishizuka Tamotsu, Takeda Takayuki, Kawasaki Masayuki, Goto Yasuhiro, Imai Hisao, Hattori Noboru, Nakatomi Keita, Uramoto Hidetaka, Uryu Kiyoaki, Fukuda Minoru, Uchida Yasuki, Yokoyama Toshihide, Akai Masaya, Mio Tadashi, Nagashima Seiji, Chihara Yusuke, Tamiya Nobuyo, Kaneko Yoshiko, Mouri Takako, Yamada Tadaaki, Yoshimura Kenichi, Fujita Masaki, Takayama Koic |
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 5 38 (19): 2187-2196. Kenmotsu Hirotsugu, Yamamoto Nobuyuki, Yamanaka Takeharu, Yoshiya Katsuo, Takahashi Toshiaki, Ueno Tsuyoshi, Goto Koichi, Daga Haruko, Ikeda Norihiko, Sugio Kenji, Seto Takashi, Toyooka Shinichi, Date Hiroshi, Mitsudomi Tetsuya, Okamoto Isamu, Yokoi Kohei, Saka Hideo, Okamoto Hiroaki, Takiguchi Yuichi, Tsuboi Masahi |
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thoracic cancer 2020 Mar . Kishikawa Takayuki, Kasai Takashi, Okada Masahiko, Nakachi Ichiro, Soda Sayo, Arai Ryo, Takigami Ayako, Sata Masafu |
Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. Journal of the Formosan Medical Association = Taiwan yi zhi 2020 1 119 (10): 1506-1513. Chen Chung-Yu, Chen Kuan-Yu, Shih Jin-Yuan, Yu Chong-J |
First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in oncology 2021 4 11 598265. Wu Qiang, Luo Wuxia, Li Wen, Wang Ting, Huang Lin, Xu Fe |
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer chemotherapy and pharmacology 2021 11 89 (1): 105-115. Padda Sukhmani K, Reckamp Karen L, Koczywas Marianna, Neal Joel W, Kawashima Jun, Kong Shengchun, Huang Daniel B, Kowalski Mark, Wakelee Heather |
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). International journal of cancer 2021 Feb 148 (3): 682-691. Assenat Eric, Mineur Laurent, Mollevi Caroline, Lopez-Crapez Evelyne, Lombard-Bohas Catherine, Samalin Emmanuelle, Portales Fabienne, Walter Thomas, de Forges Hélène, Dupuy Marie, Boissière-Michot Florence, Ho-Pun-Cheung Alexandre, Ychou Marc, Mazard Thiba |
PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. Journal of cancer research and clinical oncology 2022 7 148 (12): 3557-3566. Zhu Yixiang, Zhang Ye, Hu Xingsheng, Wang Mingzhao, Wang Hongyu, Liu Yut |
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 2023 5 11 (5): . Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouz |
A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in Combination with Cetuximab and Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 11 . Nuttapong Ngamphaiboon, Poompis Pattaranutaporn, Somthawin Lukerak, Teerada Siripoon, Artit Jinawath, Lalida Arsa, Prapimporn Ch Shantavasinkul, Naphat Taonam, Narumol Trachu, Natini Jinawath, Arpakorn Kositwattanarerk, Thiparom Sananmuang, Chuleeporn Jiarpinitn |
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. Nature communications 2024 8 15 (1): 7255. Xiaojing Xu, Luoyan Ai, Keshu Hu, Li Liang, Minzhi Lv, Yan Wang, Yuehong Cui, Wei Li, Qian Li, Shan Yu, Yi Feng, Qing Liu, Ying Yang, Jiao Zhang, Fei Xu, Yiyi Yu, Tianshu L |
First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation. BMC cancer 2024 10 24 (1): 1326. Yanjuan Xiong, Lu Wang, Weihong Zhang, Yuan Meng, Yang Wang, Meng Shen, Li Zhou, Runmei Li, Yingge Lv, Shengguang Wang, Xiubao Ren, Liang L |
- Page last reviewed:Feb 1, 2024
- Content source: